文献速递前列腺癌

WOMBAT研究:双相雄激素治疗用于达罗他胺进展的非转移性去势抵抗性前列腺癌

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.
PubMed 文献 · Eur Urol Oncol · 2026-02-21

WOMBAT是一项前瞻性、单臂、多中心2期试验,计划入组约69例在达罗他胺治疗下仅生化进展的非转移性去势抵抗性前列腺癌(nmCRPC)患者,评估双相雄激素治疗(BAT)的疗效与安全性。主要终点为无转移生存期(MFS),采用Simon最优两阶段设计并设无效性中期分析,检测MFS显著改善(风险比约0.68)的把握度为80%。

要点

  • 首个在达罗他胺进展的nmCRPC中评估BAT的研究
  • BAT每56天为一周期,序贯肌注睾酮与间歇口服达罗他胺,持续雄激素剥夺治疗为背景
  • 主要终点为MFS,次要终点包括安全性、PSA缓解率、PSA进展时间、健康相关生活质量及代谢与骨转换标志物变化

核心结论

  • WOMBAT将评估BAT在达罗他胺治疗后生化进展的nmCRPC患者中的疗效与安全性,以期通过再敏化延长达罗他胺治疗窗口并延迟转移。

研究设计与样本

  • WOMBAT为前瞻性、单臂、多中心2期试验,计划入组约69例参与者。
  • 采用Simon最优两阶段设计并设无效性中期分析,检测MFS显著改善(风险比约0.68)的把握度为80%。
  • 患者接受56天治疗周期,包括序贯肌注睾酮和间歇口服达罗他胺,并持续雄激素剥夺治疗为背景,治疗至进展,随访24个月。

关键数值与推荐

  • 主要终点为MFS;次要终点包括安全性与耐受性、PSA缓解率、PSA进展时间、健康相关生活质量及代谢与骨转换标志物变化。

临床怎么用

  • 若研究达到主要终点,BAT可能为达罗他胺进展的nmCRPC提供一种再敏化策略,以延迟转移并改善生活质量与骨密度。

局限性

  • 单臂设计是局限性。
  • MFS虽为监管接受的主要终点,但对该新型治疗策略并非总生存的已验证替代指标,因干预可能影响进展后生存。
  • 常规影像可能将BAT期间的早期变化误判为真性疾病进展;每8周一次的影像计划虽与既往BAT试验一致,但可能无法充分捕捉短暂「闪烁」现象。
  • BAT与达罗他胺的最佳循环持续时间未知;根据既往经验,睾酮恢复至去势水平需长达四个半衰期(约28-36天),因此每个56天周期可能不足以在后续睾酮给药前诱导最大且持久的达罗他胺再敏化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Resistance to androgen receptor pathway inhibitors (ARPIs) such as darolutamide signals impending metastatic progression of prostate cancer (PC) with limited subsequent therapeutic options. It has been shown that bipolar androgen therapy (BAT) resensitizes castration-resistant PC (CRPC) cells to ARPIs. The objective of the WOMBAT trial is to evaluate the efficacy and safety of BAT in men with nonmetastatic CRPC (nmCRPC) experiencing biochemical-only progression on darolutamide. CLINICAL TRIAL DESIGN AND TIMEFRAME: WOMBAT is a prospective, single-arm, multicenter, phase 2 trial enrolling ∼69 participants. The trial uses a Simon optimal two-stage design with an interim futility analysis, which provides 80% power for detection of a clinically significant improvement in metastasis-free survival (MFS; hazard ratio ∼0.68). Patients receive 56-d treatment cycles comprising sequential intramuscular testosterone and intermittent oral darolutamide on a continuous androgen deprivation therapy backbone. Treatment continues until progression, with a 24-mo follow-up period. ENDPOINTS: The primary endpoint is MFS. Secondary endpoints include safety and tolerability, the prostate-specific antigen (PSA) response rate, time to PSA progression, health-related quality of life (HRQoL), and changes in metabolic and bone turnover markers. STRENGTHS AND LIMITATIONS: This is the first trial to investigate BAT in the specific clinical setting of nmCRPC progression on darolutamide. Strengths include a strong biological rationale and extensive collection of translational and HRQoL data. The single-arm design is a limitation. Furthermore, while MFS is a regulatory-accepted primary endpoint in this disease state, it is not a validated surrogate for overall survival for this novel therapeutic strategy, as the intervention could theoretically impact postprogression survival. A further limitation is the potential for conventional imaging to misinterpret early changes during BAT as true disease progression. The imaging schedule (every 8 wk), while aligned with prior BAT trials for comparability, may not fully capture transient "flare" phenomena that could precede a response to subsequent intermittent darolutamide. Finally, the optimal duration for cycling of BAT and darolutamide is unknown. According to prior experience, a return to castrate testosterone levels can take up to four half-lives (∼28-36 d). Therefore, a limitation of the study is that each 56-d cycle may be insufficient to induce maximum and durable resensitization to darolutamide before subsequent testosterone administration. FUNDING: WOMBAT is funded by a grant from Bayer to ANZUP. ANZUP also receives infrastructure funding from the Australian Government via Cancer Australia. ETHICS AND TRIAL REGISTRATION: The trial has been approved by the ethics committee of St. Vincent's Hospital Sydney and is registered on ANZCTR (ACTRN12624000582550) and ClinicalTrials.gov (NCT06594926). PATIENT SUMMARY: Men with prostate cancer that is no longer controlled by standard hormone therapies are at risk of cancer progression. This study will test an experimental treatment called bipolar androgen therapy (BAT). BAT uses high-dose testosterone in cycles to see if it can resensitize the cancer cells to treatment and delay the spread of cancer to other parts of the body. CLINICAL TRIAL IN CONTEXT: Resistance to androgen receptor pathway inhibitors (ARPIs) such as darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC) signals impending metastatic progression, so there is a clinical unmet need in this setting. Although bipolar androgen therapy (BAT) can resensitize tumors to ARPIs in metastatic CRPC, its efficacy in preventing or delaying metastasis in nmCRPC has not yet been evaluated. WOMBAT is a prospective, multicenter, single-arm, phase 2 study enrolling ∼69 participants with nmCRPC experiencing biochemical progression on darolutamide. Participants receive treatment comprising high-dose intramuscular testosterone (BAT) followed by intermittent darolutamide, maintained on a backbone of continuous androgen deprivation therapy in 56-d cycles. The primary endpoint is metastasis-free survival. This trial is investigating a novel strategy to extend the darolutamide therapeutic window and delay metastasis by resensitizing cancer cells to androgen receptor inhibition. Uniquely, cyclical administration of supraphysiologic testosterone has the potential to alleviate the cumulative toxicity of long-term castration and thus to offer improvements in health-related quality of life and bone mineral density. As the first study to investigate BAT in nmCRPC, WOMBAT could establish a new treatment paradigm for darolutamide-refractory disease.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Talmor B, Harris CA, Gianacas C, et al. WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide. Eur Urol Oncol. 2026. PMID: 41724634. doi:10.1016/j.euo.2026.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。